Shandong Xinhua Pharmaceutical Company Limited Class H (0719) Stock Statistics & Valuation Metrics

Shandong Xinhua Pharmaceutical Company Limited Class H has a market cap or net worth of HK$9.89B. The enterprise value is HK$0.00.

Shandong Xinhua Pharmaceutical Company Limited Class H has 195,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shandong Xinhua Pharmaceutical Company Limited Class H’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 7.16%.

The current PE Ratio of Shandong Xinhua Pharmaceutical Company Limited Class H is 11.2. Shandong Xinhua Pharmaceutical Company Limited Class H’s PEG ratio is -1.90.

In the last 12 months, Shandong Xinhua Pharmaceutical Company Limited Class H had revenue of 8.47B and earned 470.02M in profits. Earnings per share was 0.69.

In the last 12 months, operating cash flow was 339.26M and capital expenditures -107.20M, giving a free cash flow of 282.70M billion.

Shandong Xinhua Pharmaceutical Company Limited Class H pays an annual dividend of HK$0.273, resulting in a dividend yield of 4.49%

Shandong Xinhua Pharmaceutical Company Limited Class H upcoming earnings date is Apr 1, 2026, TBA (Confirmed).

Shandong Xinhua Pharmaceutical Company Limited Class H as a current ratio of 1.33, with Debt / Equity ratio of 40.25%

In the past 12 months, Shandong Xinhua Pharmaceutical Company Limited Class H has paid 46.94M in taxes.

Shandong Xinhua Pharmaceutical Company Limited Class H EV to EBITDA ratio is 3.44, with an EV/FCF ratio of 24.69.

Shandong Xinhua Pharmaceutical Company Limited Class H has HK$1.35B in cash and marketable securities with HK$2.27B in debt, giving a net cash position of -HK$916.08M billion.

Gross margin is 19.39%, with operating margin of 6.31%, and net profit margin of 5.55%.

The average price target for Shandong Xinhua Pharmaceutical Company Limited Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―